A Phase I Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Combination Therapy with Refametinib plus Sorafenib in Patients with Advanced Cancer

201521 citationsJournal Articlebronze Open Access

Authors

Alex A. Adjei · Roswell Park Comprehensive Cancer Center

Donald Richards · Texas Oncology

Anthony B. El-Khoueiry · University of Southern California

Fadi Braiteh · The US Oncology Network

Carlos H.R. Becerra · Texas Oncology

Joe Stephenson · Translational Research in Oncology

Aram F. Hezel

Abstract

In this phase I study, refametinib plus sorafenib was well tolerated, with good oral absorption, near-dose proportionality, and target inhibition in a range of tumor types. Clin Cancer Res; 22(10); 2368-76. ©2015 AACR.

Topics & Keywords

Melanoma and MAPK Pathways Colorectal Cancer Treatments and Studies PI3K/AKT/mTOR signaling in cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 22, Issue 10, pp. 2368-2376

DOI: 10.1158/1078-0432.ccr-15-1681

Field-Weighted Citation Impact: 0.74